English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Triple‐negative breast cancer ( TNBC ) is highly clinically aggressive and taxol‐based chemoresistance remains a big  TNBC  therapeutic problem to be solved. Verteporfin, a small molecular yes‐associated protein 1 ( YAP 1) inhibitor, is little known as an antitumor drug for  TNBC . Our data showed that  YAP 1 expression was associated with early relapse in tissue samples of patients with  TNBC  taxol chemoresistance ( P  < .001). Verteporfin reduced migration and enhanced apoptosis or autophagy of a taxol‐resistant  MDA ‐ MB ‐231 cell line in vitro. Knockdown of  YAP 1 increased epithelial‐mesenchymal transition response in a taxol‐resistant  TNBC  cell line. In an in vivo experiment, we found that verteporfin was able to shrink tumor weight and volume and decreased Ki67 expression in a taxol‐resistant mouse model. Our results provide evidence that verteporfin could be a chemosensitizer for  TNBC  patients with taxol‐based treatment.

Role of inhibitor of yes‐associated protein 1 in triple‐negative breast cancer with taxol‐based chemoresistance